Navigation Links
Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
Date:2/3/2009

Intellectual property based on breakthrough research from a team led by Dr. Jean-Claude Tardif at the Montreal Heart Institute Research Centre, Canada.

TOULOUSE, France and ANN ARBOR, Mich., Feb. 3 /PRNewswire/ -- Cerenis Therapeutics SA (Cerenis), a privately held pharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, today announced that it has in-licensed intellectual property supporting an investigational new treatment of aortic valve stenosis (AVS) based on HDL therapy. This technology is based on the findings of a study led by Jean-Claude Tardif, M.D. at the Montreal Heart Institute Research Centre in Canada.

AVS is characterized by a narrowing of the aortic valve, which can obstruct the flow of oxygenated blood from the heart to the rest of the body. As the heart works harder to compensate for the obstruction, the heart muscle thickens and can cause a potentially dangerous imbalance in blood pressure between the heart and body. Symptoms of severe AVS can include angina and syncope (fainting), and major complications can include heart failure and sudden death. AVS is the most common form of heart valve disease in Western countries, resulting in more than 50,000 aortic valve replacement surgeries each year in the U.S.

In Dr. Tardif's placebo-controlled study in rabbit AVS models, the aortic valve opening in the treatment group returned to a near-normal state and aortic valve thickness was significantly decreased after 14 days of treatment. In addition, the treatment group showed significantly less extensive valve lesions than the control group as well as reduced aortic valve calcification. Results of the study were published in April 2008 in the British Journal of Pharmacology.

"We are very pleased to add this exciting new intellectual property to our growing portfolio of HDL therapies," said Jean-Louis Dasseux, Ph.D.,
'/>"/>

SOURCE Cerenis Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
2. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
3. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
4. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
5. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
6. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
7. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
8. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
11. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Baptist Health Lexington ... to receive full Atrial Fibrillation with Electrophysiology Services ... (SCPC). Atrial fibrillation is the most common cardiac ... in some cases can lead to stroke and possible death. ... States have atrial fibrillation and the numbers are ...
(Date:12/17/2014)... DIEGO , Dec. 17, 2014 Royal ... Volcano Corporation (NASDAQ: VOLC ), a global leader ... announced that they have entered into a definitive merger agreement. ... to acquire all of the issued and outstanding shares of ... purchase price of USD 1 billion (approx. EUR 800 million), ...
(Date:12/17/2014)... YORK , Dec. 17, 2014 ... imaging (MRI), the MRI market is seeing new ... and breast MRI scans account for the majority ... a higher resolution of images, which are creating opportunities ... imaging (MRI) market is growing at a rate ...
Breaking Medicine Technology:Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3
... a drug,and diagnostic discovery company, announced today the ... of its lead compound, EHT 0202, on,scopolamine-induced brain ... with a novel mechanism of action, which has ... is currently tested in a Phase 2,clinical trial ...
... save part of each kidney in patients with,bilateral ... on preoperative,scans, MEMPHIS, Tenn., March 24 ... children with bilateral,Wilms tumor, a cancer of the ... undergoing a procedure called bilateral nephron-sparing surgery,even when ...
Cached Medicine Technology:ExonHit's EHT 0202 Counters Scopolamine's Detrimental Effects on Cognition in Humans 2ExonHit's EHT 0202 Counters Scopolamine's Detrimental Effects on Cognition in Humans 3ExonHit's EHT 0202 Counters Scopolamine's Detrimental Effects on Cognition in Humans 4St. Jude Study Offers New Hope for Children With Kidney Tumors Deemed Inoperable 2
(Date:12/20/2014)... Dec. 20, 2014 (HealthDay News) -- The holidays can ... they contend with fresh trees, scented candles and other ... on the decorations that have been packed away in ... my allergy and asthma patients," Dr. Rachna Shah, an ... of Medicine, said in Loyola news release. Shah, ...
(Date:12/20/2014)... New York (PRWEB) December 20, 2014 ... continue to move forward in U.S. courts, Bernstein ... study which suggests that children treated with the ... hormone linked to breast development and lactation. The ... at 34 children and adolescents who began treatment ...
(Date:12/20/2014)... December 20, 2014 Developers of ... of a new plugin for Final Cut Pro X ... “TranSlice Volume 5 allows users to create hand drawn ... Said Christina Austin, CEO of Pixel Film Studios. “TranSlice ... professionalism while maintaining an easy to use interface.” , ...
(Date:12/20/2014)... Today, Balfleet.com, one of the most outstanding dressmakers ... off on its Mother of the Bride Dresses ... the bride dresses from Balfleet.com feature gorgeous looks and ... takes pride in providing high quality dresses to its ... discounts on our mother of the bride dresses, and ...
(Date:12/19/2014)... Sarasota, Florida (PRWEB) December 19, 2014 Sub ... Bank to sponsor a blood drive Sunday the 28th from ... Clark Road & Sawyer Road in Sarasota, FL. , Inquiries ... special thank you for participating in the donating process, Sub ... a free flash frozen, custom ice cream. , About Sub ...
Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2
... SATURDAY, Aug. 20 (HealthDay News) -- Working moms are less ... new study finds. However, working moms who don,t cut ... it will be to balance work and family have higher ... Researchers analyzed survey results from 1,600 married U.S. women who ...
... discovered a key mechanism used by intestinal cells to ... hospital-acquired bacterial infections a mechanism they think they ... the effects of the antibiotic-resistant bacteria. The scientists ... powerful toxins generated by the bacteria Clostridium difficile ...
... Aug. 20 (HealthDay News) -- Medications can be harmed by ... of drugs have been tested at temperatures above 86F, all ... According to Dr. Amy Peak, clinical pharmacist and director ... been tested at high temperatures. She outlined some of the ...
... , FRIDAY, Aug. 19 (HealthDay News) -- ... respiratory illnesses have pertussis, a highly contagious childhood disease ... The findings should reassure doctors they aren,t ... a distinctive-sounding and uncontrollable cough. In conducting the ...
... to 24 is rising rapidly according to a study conducted by ... The study appears in the "First Look" online version of ... increased popularity of the hookah a water pipe used for ... the behavior coupled with the misguided belief that it is less ...
... Reporter , FRIDAY, Aug. 19 (HealthDay News) -- At 3 years ... had quit growing. He also had frequent severe constipation, so much ... mother, Andrea Levario of Alexandria, Va. Because of the prolapse, ... from the body, doctors worried that the boy, who is now ...
Cached Medicine News:Health News:Trying to Be 'Supermom' Can Raise Risk for Depression 2Health News:Trying to Be 'Supermom' Can Raise Risk for Depression 3Health News:New defense discovered against common hospital-acquired infection 2Health News:Excessive Heat Can Harm Medications, Expert Says 2Health News:Kids' Hacking Is Seldom Whooping Cough, Study Finds 2Health News:UCSD researchers alarmed at rise in hookah use among California youth 2Health News:Gluten-Free Set This Boy Free 2
Colloidal Gold Sol, 20 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 20 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
CranioFix2 is the next generation CranioFix Titanium Clamp System, which is up to 40% faster than the original CranioFix and all flap fixation systems on the market....
... is an accurate, reliable, portable, and ... It works off of a dual-rechargeable ... the device a breeze. The large, ... operating and viewing results simple. Built ...
Medicine Products: